Skip to main content
Top
Published in: Diabetes Therapy 5/2017

Open Access 01-10-2017 | Review

Efficacy and Time Sensitivity of Amniotic Membrane treatment in Patients with Diabetic Foot Ulcers: A Systematic Review and Meta-analysis

Authors: Irakoze Laurent, Manirakiza Astère, Kan Ran Wang, Qing-feng Cheng, Qi Fu Li

Published in: Diabetes Therapy | Issue 5/2017

Login to get access

Abstract

Introduction

Diabetic foot ulcers (DFUs) are complex chronic wounds which have a major long-term impact on the morbidity, mortality and quality of patients. The objective of this study was to assess the efficacy and time sensitivity of human amnion/chorion membrane treatment in patients with chronic DFUs.

Methods

The Cochrane Library, PubMed, Embase and Web of Science databases were systematically searched to identify relevant articles up to 10 April 2017. All randomized controlled trials (RCTs) comparing human amnion/chorion membrane + standard therapy and standard therapy alone in patients with DFUs were included in the analysis. Eligible studies were reviewed and data extracted into standard form. The Cochrane Collaboration’s tool for assessing the risk of bias was used. Review manager version 5.3 software was used for statistical analysis. Data were analyzed using a random effect model.

Results

Overall, the initial search of the four databases identified 352 published studies; of these, seven RCTS were ultimately included in the meta-analysis. The overall test effect in the group assessed at 4 weeks was Z = 4.14 [P < 0.0001; odds ratio (OR) 0.05; 95% confidence interval (CI) 0.01–0.21]. The overall test effect in the group assessed at 6 weeks was Z = 4.28 (P < 0.0001; OR 0.07; 95% CI 0.02–0.23). The overall effect in the group assessed at 12 weeks was Z = 4.96 (P < 0.00001; OR 0.10; 95% CI 0.04–0.24. The results showed that patients receiving amniotic membrane + standard therapy had far fewer incomplete healing wounds than those receiving standard of care alone. Assessment of the wound healing state at 4 and 6 weeks revealed that the wound healing state was almost the same, but there was a net difference of wound healing state at 12 weeks.

Conclusion

Human amnion/chorion membrane + standard of care treatment heals DFUs significantly faster than standard of care alone. When using the amnion in patients with DFUs, the optimal times to assess progress in wound healing should be 4 and 12 weeks.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Haria JM, Singh VK, Jain SK. Life with diabetic foot ulcer—a cross sectional study. Int J Sci Study. 2014;1(6):33–5. Haria JM, Singh VK, Jain SK. Life with diabetic foot ulcer—a cross sectional study. Int J Sci Study. 2014;1(6):33–5.
3.
go back to reference Centre for Clinical Practice at National Institute for Health and Clinical Excellence (2011) Guidance. Diabetic foot problems: inpatient management of diabetic foot problems. National Institute for Health and Clinical Excellence, London. Centre for Clinical Practice at National Institute for Health and Clinical Excellence (2011) Guidance. Diabetic foot problems: inpatient management of diabetic foot problems. National Institute for Health and Clinical Excellence, London.
4.
go back to reference Brownrigg JR, Davey J, Holt PJ, Davis WA, Thompson MM, Ray KK, Hinchliffe RJ. The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis. Diabetologia. 2012;55(11):2906–12. doi:10.1007/s00125-012-2673-3.CrossRefPubMed Brownrigg JR, Davey J, Holt PJ, Davis WA, Thompson MM, Ray KK, Hinchliffe RJ. The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis. Diabetologia. 2012;55(11):2906–12. doi:10.​1007/​s00125-012-2673-3.CrossRefPubMed
5.
go back to reference Kirsner RS, Sabolinski ML, Parsons NB, Skornicki M, Marston WA. Comparative effectiveness of a bioengineered living cellular construct vs. a dehydrated human amniotic membrane allograft for the treatment of diabetic foot ulcers in a real world setting. Wound Repair Regen. 2015;23(5):737–44. doi:10.1111/wrr.12332.CrossRefPubMed Kirsner RS, Sabolinski ML, Parsons NB, Skornicki M, Marston WA. Comparative effectiveness of a bioengineered living cellular construct vs. a dehydrated human amniotic membrane allograft for the treatment of diabetic foot ulcers in a real world setting. Wound Repair Regen. 2015;23(5):737–44. doi:10.​1111/​wrr.​12332.CrossRefPubMed
6.
go back to reference Metelko Z, Brkljacic Crkvencic N. Prevention of diabetic foot. Acta Med Croatica. 2013;67(Suppl 1):35–44. Metelko Z, Brkljacic Crkvencic N. Prevention of diabetic foot. Acta Med Croatica. 2013;67(Suppl 1):35–44.
7.
go back to reference Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E. Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132–73. doi:10.1093/cid/cis346.CrossRefPubMed Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E. Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132–73. doi:10.​1093/​cid/​cis346.CrossRefPubMed
10.
go back to reference Wilbek TE, Jansen RB, Jorgensen B, Svendsen OL. The diabetic foot in a multidisciplinary team setting. Number of amputations below ankle level and mortality. Exp Clin Endocrinol Diabetes. 2016;124(9):535–40. doi:10.1055/s-0042-109260.CrossRefPubMed Wilbek TE, Jansen RB, Jorgensen B, Svendsen OL. The diabetic foot in a multidisciplinary team setting. Number of amputations below ankle level and mortality. Exp Clin Endocrinol Diabetes. 2016;124(9):535–40. doi:10.​1055/​s-0042-109260.CrossRefPubMed
13.
15.
go back to reference Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, Driver VR, Frykberg R, Carman TL, Marston W, Mills JL Sr, Murad MH. The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63(2 Suppl):3s–21s. doi:10.1016/j.jvs.2015.10.003.CrossRefPubMed Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, Driver VR, Frykberg R, Carman TL, Marston W, Mills JL Sr, Murad MH. The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63(2 Suppl):3s–21s. doi:10.​1016/​j.​jvs.​2015.​10.​003.CrossRefPubMed
17.
go back to reference Hawkins B. The use of micronized dehydrated human amnion/chorion membrane allograft for the treatment of diabetic foot ulcers: a case series. Wounds Compend Clin Res Pract. 2016;28(5):152–7. Hawkins B. The use of micronized dehydrated human amnion/chorion membrane allograft for the treatment of diabetic foot ulcers: a case series. Wounds Compend Clin Res Pract. 2016;28(5):152–7.
18.
go back to reference Rosenblum BI. A retrospective case series of a dehydrated amniotic membrane allograft for treatment of unresolved diabetic foot ulcers. J Am Podiatr Med Assoc. 2016;106(5):328–37. doi:10.7547/15-139.CrossRefPubMed Rosenblum BI. A retrospective case series of a dehydrated amniotic membrane allograft for treatment of unresolved diabetic foot ulcers. J Am Podiatr Med Assoc. 2016;106(5):328–37. doi:10.​7547/​15-139.CrossRefPubMed
19.
20.
go back to reference Massee M, Chinn K, Lim JJ, Godwin L, Young CS, Koob TJ. Type I and II diabetic adipose-derived stem cells respond in vitro to dehydrated human amnion/chorion membrane allograft treatment by increasing proliferation, migration, and altering cytokine secretion. Adv Wound Care. 2016;5(2):43–54. doi:10.1089/wound.2015.0661.CrossRef Massee M, Chinn K, Lim JJ, Godwin L, Young CS, Koob TJ. Type I and II diabetic adipose-derived stem cells respond in vitro to dehydrated human amnion/chorion membrane allograft treatment by increasing proliferation, migration, and altering cytokine secretion. Adv Wound Care. 2016;5(2):43–54. doi:10.​1089/​wound.​2015.​0661.CrossRef
21.
go back to reference Wilshaw SP, Kearney J, Fisher J, Ingham E. Biocompatibility and potential of acellular human amniotic membrane to support the attachment and proliferation of allogeneic cells. Tissue Eng Part A. 2008;14(4):463–72. doi:10.1089/tea.2007.0145.CrossRefPubMed Wilshaw SP, Kearney J, Fisher J, Ingham E. Biocompatibility and potential of acellular human amniotic membrane to support the attachment and proliferation of allogeneic cells. Tissue Eng Part A. 2008;14(4):463–72. doi:10.​1089/​tea.​2007.​0145.CrossRefPubMed
22.
go back to reference Duan-Arnold Y, Uveges TE, Gyurdieva A, Johnson A, Danilkovitch A. Angiogenic potential of cryopreserved amniotic membrane is enhanced through retention of all tissue components in their native state. Adv Wound Care. 2015;4(9):513–22. doi:10.1089/wound.2015.0638.CrossRef Duan-Arnold Y, Uveges TE, Gyurdieva A, Johnson A, Danilkovitch A. Angiogenic potential of cryopreserved amniotic membrane is enhanced through retention of all tissue components in their native state. Adv Wound Care. 2015;4(9):513–22. doi:10.​1089/​wound.​2015.​0638.CrossRef
25.
go back to reference Zelen CM, Gould L, Serena TE, Carter MJ, Keller J, Li WW. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015;12(6):724–32. doi:10.1111/iwj.12395.CrossRefPubMed Zelen CM, Gould L, Serena TE, Carter MJ, Keller J, Li WW. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015;12(6):724–32. doi:10.​1111/​iwj.​12395.CrossRefPubMed
27.
go back to reference Mohajeri-Tehrani MR, Variji Z, Mohseni S, Firuz A, Annabestani Z, Zartab H, Rad MA, Tootee A, Dowlati Y, Larijani B. Comparison of a bioimplant dressing with a wet dressing for the treatment of diabetic foot ulcers: a randomized, controlled clinical trial. Wounds Compend Clin Res Pract. 2016;28(7):248–54. Mohajeri-Tehrani MR, Variji Z, Mohseni S, Firuz A, Annabestani Z, Zartab H, Rad MA, Tootee A, Dowlati Y, Larijani B. Comparison of a bioimplant dressing with a wet dressing for the treatment of diabetic foot ulcers: a randomized, controlled clinical trial. Wounds Compend Clin Res Pract. 2016;28(7):248–54.
28.
go back to reference Snyder RJ, Shimozaki K, Tallis A, Kerzner M, Reyzelman A, Lintzeris D, Bell D, Rutan RL, Rosenblum B. A prospective, randomized, multicenter, controlled evaluation of the use of dehydrated amniotic membrane allograft compared to standard of care for the closure of chronic diabetic foot ulcer. Wounds Compend Clin Res Pract. 2016;28(3):70–7. Snyder RJ, Shimozaki K, Tallis A, Kerzner M, Reyzelman A, Lintzeris D, Bell D, Rutan RL, Rosenblum B. A prospective, randomized, multicenter, controlled evaluation of the use of dehydrated amniotic membrane allograft compared to standard of care for the closure of chronic diabetic foot ulcer. Wounds Compend Clin Res Pract. 2016;28(3):70–7.
29.
go back to reference Zelen CM, Serena TE, Gould L, Le L, Carter MJ, Keller J, Li WW. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J. 2016;13(2):272–82. doi:10.1111/iwj.12566.CrossRefPubMed Zelen CM, Serena TE, Gould L, Le L, Carter MJ, Keller J, Li WW. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J. 2016;13(2):272–82. doi:10.​1111/​iwj.​12566.CrossRefPubMed
30.
go back to reference Lavery LA, Fulmer J, Shebetka KA, Regulski M, Vayser D, Fried D, Kashefsky H, Owings TM, Nadarajah J. The efficacy and safety of Grafix ((R)) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11(5):554–60. doi:10.1111/iwj.12329.CrossRefPubMed Lavery LA, Fulmer J, Shebetka KA, Regulski M, Vayser D, Fried D, Kashefsky H, Owings TM, Nadarajah J. The efficacy and safety of Grafix ((R)) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11(5):554–60. doi:10.​1111/​iwj.​12329.CrossRefPubMed
32.
go back to reference Sorsby A, Symons HM. Amniotic membrane grafts in caustic burns of eye: (Burns of the second degree). Br J Ophthalmol. 1946;30(6):337–45.CrossRefPubMedCentral Sorsby A, Symons HM. Amniotic membrane grafts in caustic burns of eye: (Burns of the second degree). Br J Ophthalmol. 1946;30(6):337–45.CrossRefPubMedCentral
34.
37.
go back to reference Mao Y, Hoffman T, Johnson A, Duan-Arnold Y, Danilkovitch A, Kohn J. Human cryopreserved viable amniotic membrane inhibits the growth of bacteria associated with chronic wounds. J Diabet Foot Compl. 2016;8(2):23–30. Mao Y, Hoffman T, Johnson A, Duan-Arnold Y, Danilkovitch A, Kohn J. Human cryopreserved viable amniotic membrane inhibits the growth of bacteria associated with chronic wounds. J Diabet Foot Compl. 2016;8(2):23–30.
Metadata
Title
Efficacy and Time Sensitivity of Amniotic Membrane treatment in Patients with Diabetic Foot Ulcers: A Systematic Review and Meta-analysis
Authors
Irakoze Laurent
Manirakiza Astère
Kan Ran Wang
Qing-feng Cheng
Qi Fu Li
Publication date
01-10-2017
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 5/2017
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-017-0298-8

Other articles of this Issue 5/2017

Diabetes Therapy 5/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.